- Molecular NameMebendazole
- SynonymMBZ
- Weight295.298
- Drugbank_IDDB00643
- ACS_NO31431-39-7
- Show 2D model
- LogP (experiment)2.83
- LogP (predicted, AB/LogP v2.0)2.86
- pkaN/A
- LogD (pH=7, predicted)2.86
- Solubility (experiment)0.0713 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.87
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors6
- No.of Rotatable Bonds4
- TPSA84.08
- StatusFDA approved
- AdministrationN/A
- PharmacologyA benzimidazole drug that is used to treat infestations by worms including pinworms, roundworms, tapeworms, hookworms, and whipworms.
- Absorption_value6.0
- Absorption (description)Mebendazole is poorly absorbed after oral administration.
- Caco_2N/A
- Bioavailability6.0
- Protein binding95.0
- Volume of distribution (VD)2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is metabolised to the 5-(α-hydroxy) derivative and by decarboxylation to the 2-amino metabolite, both of which are detectable in plasma at concentrations higher than those of unchanged mebendazole.
- Half life2.5~5.5 h (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).
- ExcretionLess than 10% of a dose is excreted in the urine; the major urinary metabolite is the 2-amino-5-(α-hydroxy) derivative. Biliary excretion and enterohepatic circulation have been reported.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.
- LD50 (rat)N/A
- LD50 (mouse)LD50=620 mg/kg